Taking these data one step further, we used UALCAN to analyze OS between FLT3-mutated AML patients with high versus low PSMD1 expression, which again had no effect on OS (p = 0.3, Figure 1C). This evidence concerns the gene FLT3 and acute myeloid leukemia.